Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Panlin Capital (磐霖资本) is a Shanghai-based venture capital firm founded by Li Yuhui, focusing on innovative biopharmaceuticals, medical devices, and technology services. Established to address unmet clinical needs, the firm has raised over RMB 1.5 billion across its healthcare VC fund in a two-year period from 2022 to 2023. This capital influx reflects a strong LP re-investment rate exceeding 40%, indicating confidence in Panlin's investment strategy.
The firm operates from its headquarters in Shanghai, with additional offices in Hangzhou and Chengdu. Panlin Capital primarily invests in early to growth-stage companies, targeting sectors such as life sciences, biotechnology, and technology services. The firm’s investment strategy is supported by China's robust R&D capabilities and increasing capital availability, which are crucial for fostering innovation in the life sciences sector.
Panlin Capital's notable milestones include a significant portfolio of approximately 20 companies, many of which are leaders in their respective fields. The firm’s strategic guidance and access to a robust network of industry contacts enhance its ability to support portfolio companies effectively.
Panlin Capital invests in companies that are pioneering solutions in life sciences, particularly those developing novel therapeutics and medical devices. Their investment strategy emphasizes early to growth-stage companies that demonstrate potential for significant impact in healthcare and technology. The firm focuses on sectors including biotech, healthcare, and AI, with a particular interest in B2B enterprises that enhance operational efficiency and ensure technology autonomy.
The firm’s investment stages range from pre-seed to growth equity, allowing them to engage with startups at various points in their development. Panlin Capital seeks companies that address critical clinical needs and enhance technology autonomy, particularly in the context of innovative drug development and medical device research. Their thesis underscores the importance of early-stage investments in China, leveraging strong domestic R&D talent and government-backed industrial support.
Panlin Capital's portfolio includes approximately 20 companies, showcasing a diverse range of innovative solutions in the healthcare and technology sectors. Notable portfolio companies include:
This portfolio reflects Panlin Capital's commitment to supporting companies that address unmet clinical needs and enhance operational efficiencies through innovative solutions.
Li Yuhui: Founding Managing Partner. Li is known for his precision and conviction in early-stage biotech investments, often referred to as a 'sniper' investor.
薛总 (Xue): Partner with extensive experience in venture capital and a focus on life sciences.
杜伟民 (Du Weimin): Chairman of Kangtai Biological, bringing significant industry expertise to the firm.
管乔中 (Guan Qiaozhong): Founder and General Manager of Capbio, contributing insights into cervical cancer screening innovations.
凌锦明 (Ling Jinming): Vice Chairman of High Energy Environment, with a background in technology services.
梁子才 (Liang Zicai): Founder and CEO of Rebio, specializing in small nucleic acid therapeutics.
廖杨 (Liao Yang): Co-founder of XGIMI, known for advancements in smart technology.
吕强 (Lü Qiang): Founder and Chairman of JinFang Pharmaceutical, focusing on new drug development.
郑瑞祥 (Zheng Ruixiang): Founder and Chairman of Ruiyun Cold Chain, contributing to logistics innovations.
陈东坡 (Chen Dongpo): Founder of ChuanTu Microelectronics, with expertise in electronic design.
朱洪涛 (Zhu Hongtao): Founder and CEO of Yimai Gongpin, focusing on technology solutions.
刘辰 (Liu Chen): Founder and President of Afei Biotech, specializing in tumor microenvironment-responsive drug development.
姚欣 (Yao Xin): Co-founder of PPIO, contributing to operational efficiency innovations.
程新 (Cheng Xin): Founder of Zhixin Haozheng, with a focus on technology services.
魏星 (Wei Xing): Founder and CEO of Qijie Technology, specializing in electronic design automation software.
丁宝全 (Ding Baoquan): Founder of Dina Yuan Sheng, contributing to healthcare innovations.
陆芳 (Lu Fang): President of Baihezi Technology, focusing on technology solutions.
汤阳 (Tang Yang): Founder of Benyao Technology, with expertise in medical devices.
To pitch to Panlin Capital, founders should send their proposals via email to master@panlincap.com. It is recommended to include a comprehensive deck that outlines the business model, market opportunity, competitive landscape, and team qualifications. The firm appreciates detailed information that demonstrates the startup's potential for growth and innovation.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
In December 2023, Panlin Capital announced the second closing of its Hangzhou Panlin Xukang Fund, raising over RMB 1.5 billion in total across two years. This significant capital raise reflects the firm's strong LP re-investment rate exceeding 40%, indicating confidence in its investment strategy.
Panlin Capital has been actively identifying and supporting innovative companies in the biotech and healthcare sectors, with a notable portfolio that includes leading firms in vaccine development, smart technology, and cancer screening.
What are Panlin Capital's investment criteria?
Panlin Capital focuses on early to growth-stage companies in the biotech, healthcare, and technology sectors. They seek innovative solutions that address unmet clinical needs and enhance operational efficiency.
How can I apply or pitch to Panlin Capital?
Founders can pitch to Panlin Capital by sending an email to master@panlincap.com. It is advisable to include a detailed deck outlining the business model, market opportunity, and team background.
What makes Panlin Capital different from other VC firms?
Panlin Capital specializes in the life sciences sector, leveraging China's strong R&D capabilities and a robust network of industry contacts to support portfolio companies effectively.
What is the geographic scope of Panlin Capital's investments?
Panlin Capital primarily invests in companies based in China, particularly in Shanghai, Hangzhou, and Chengdu, but also considers globally-exposed portfolio companies.
What is the typical check size for investments?
While specific check sizes are not disclosed, Panlin Capital invests across various stages, including pre-seed, seed, and growth equity, indicating a flexible approach to funding.
What kind of post-investment involvement does Panlin Capital have?
Panlin Capital provides strategic guidance, access to a network of industry contacts, and support in navigating the complexities of the healthcare and technology sectors to its portfolio companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.